FDA OKs Unfors' PSD

TriMed Staff | | Health Imaging | Screening
Unfors has been granted 510(k) FDA approval for the Unfors PSD, Patient Skin Dosimeter.

Designed for real-time direct patient measurements of skin dose, the Unfors PSD is used during long fluoroscopic and CT procedures to prevent excessive dose usage and consequential lesions on patients.

The Unfors PSD consists of up to four unique, small sensors connected to a display unit. The small sensors can be placed anywhere on the body and will leave a minimal footprint on the X-ray image. Each sensor will display accumulated dose and exposure time. Audible and visual alarms are triggered when selected or critical dose limits are exceeded, said Unfors.

TriMed Staff

Related Content

Abbreviated MRI protocols present suitable alternatives for liver cancer screening
Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility

Around the web

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.